Alprostadil lyophilized liposomal

Drug Profile

Alprostadil lyophilized liposomal

Alternative Names: Prostaglandin E1 lyophilized liposomal

Latest Information Update: 02 Oct 2001

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioSphere Technologies; Harvard Scientific Corporation
  • Developer BioSphere Technologies; Harvard Scientific Corporation; Sae Han Pharmaceuticals
  • Class Erectile dysfunction therapies; Monounsaturated fatty acids; Muscle relaxants; Peripheral vasodilators; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin E1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Erectile dysfunction; Female sexual dysfunction; Male sexual dysfunction; Psoriasis

Most Recent Events

  • 02 Oct 2001 No-Development-Reported for Erectile dysfunction in European Union (Intrameatal)
  • 02 Oct 2001 No-Development-Reported for Erectile dysfunction in South Korea (Intrameatal)
  • 02 Oct 2001 No-Development-Reported for Erectile dysfunction in USA (Intrameatal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top